Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Measurable Residual Disease
Aims: To elucidate the clinical significance of gMRD evaluation using next generation flow cytometry (NGF) and to compare gMRD with pre-ASCT BM MRD assessment.
Methods: This single-center study included 99 newly diagnosed MM patients treated with induction therapy followed by CD34+ cell mobilization, apheresis, high-dose melphalan, and ASCT between 2019 and 2024. Grafts and paired pre-ASCT/D+100 BMs were processed according to Euroflow SOP for bulk lysis, stained for a standardized MM panel, and analyzed according to NGF MRD standards to reach the limit of detection (LOD) 0.0002% (2 x 10-6) (Flores Montero et al., 2017). BMs contaminated with peripheral blood were excluded from the analysis.
Results: The median age of patients in the cohort was 66 years and 57% were males. ISS stages: 34% I, 36% II, 29% III. Cytogenetics: 77% standard risk, 18% high risk, 5% NA. The median LOD was 0.0002% for gMRD (n = 99), as well as paired pre-ASCT BM (n = 76) and D+100 BM (n = 92). The median follow-up from the time of gMRD assessment was 29.9 months.
In total, 44% (44/99) of grafts were MRD+ with a median level of 0.0076% (range 0.0003-0.79%) of clonal plasma cells (cPCs). Levels of gMRD ≥10-4, <10-4 to ≥10-5, and <10-5 to ≥2 x 10-6 were respectively detected in 48%, 32%, and 20% of positive samples. 79% (60/76) of patients were MRD+ in pre-ASCT BM and 62% (57/92) were MRD+ at D+100. There were no significant differences in the main characteristics between gMRD+ and gMRD- subgroups except for ISS I being more prevalent in gMRD- (p = 0.04). The median PFS of the whole cohort has not been reached yet; although, in line with published data, the 2-year PFS was significantly worse for gMRD+ patients compared to gMRD- (64% vs 82%, p = 0.043). Furthermore, the number of gMRD+ patients decreased with a better post-induction response (CR = 19%, 4/21; VGPR = 33%, 14/43; PR = 74%, 23/31).
Importantly, patients who were gMRD+ were always MRD+ in the pre-ASCT BM (100%, 32/32; p < 0.001), and 83% (34/41) of patients with gMRD+ remained MRD+ in BM even at D+100 (p < 0.001). A strong correlation was confirmed between MRD levels of all (MRD+/-) paired grafts and pre-ASCT BMs (r = 0.74, p < 0.001), with a median 2-log increase in MRD levels between paired MRD+ grafts and pre-ASCT BMs (median infiltration, range: 0.01%, 0.0003-0.79% vs 1.1%, 0.0128%-21%; p < 0.001). Moreover, the gMRD+ group also had a median 2-log higher pre-ASCT MRD level compared to the gMRD- group (0.021% vs. 1.1%; p < 0.001).
Conclusion: This study, for the first time, outlines the association between easily accessible and non-invasive gMRD and pre-ASCT BM MRD assessment by NGF. Our data suggest that virtually all gMRD+ patients are also MRD+ in the pre-ASCT BM. Moreover, gMRD results provide a reliable estimate of BM MRD level with a median 2-log increase in cPC infiltration. Overall, our data imply that invasive pre-ASCT BM MRD evaluation might be omitted in gMRD+ patients, which is becoming highly relevant in the current era when the majority of patients reach deep responses after induction.
Acknowledgements: This work was supported by the European Union project LERCO (No. CZ.10.03.01/00/22_003/0000003), by the Operational Programme Just Transition; SALVAGE project CZ.02.01.01/00/22_008/0004644, supported by OP JAK, with co-financing from the EU and the State Budget.
Disclosures: Popkova: Sanofi: Other: travel support; Johnson and Johnson: Honoraria. Hajek: Takeda: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy; BMS: Consultancy, Honoraria, Research Funding; PharmaMar: Consultancy, Honoraria; Novartis: Consultancy, Research Funding. Jelinek: Sanofi: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Amgen: Research Funding; Janssen: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria.
See more of: Oral and Poster Abstracts